4D Nucleome grantee Dr. Clifford Brangwynne and collaborators have developed a new tool that uses light to manipulate matter inside living cells. Called optoDroplet, this tool helps explain the physics and chemistry behind how cells assemble a mysterious structure called a membraneless organelle. An organelle is a specialized part of a cell having some specific function. For example, the nucleus is an organelle that holds most of the cell’s genetic information. Organelles like the nucleus are walled off from the rest of the cell by a membrane. The cell also uses membraneless organelles that resemble liquid droplets and exhibit dynamic behavior, such as rapid assembly and disassembly of protein building blocks that make up the organelle. When these mechanisms go awry, aggregates of the protein building blocks can form. Protein aggregation is associated with a number of diseases, including amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) and Alzheimer's disease. Understanding the process by which proteins condense into these droplet-like, membraneless organelles may be used to develop of interventions and treatments for diseases connected with protein aggregation. To better understand this process, Dr. Brangwynne’s group developed optoDroplet. This new tool relies on optogenetics, which involves proteins whose behavior can be altered by exposure to light. Using mouse and human cells, researchers showed that they could create membraneless organelles by switching on the light-activated proteins. They were also able to use this tool to generate protein aggregates, similar to those found in some diseases. The optoDroplet system will help researchers understand the basic mechanisms that underlie self-assembly of membraneless organelles in healthy living cells and may reveal how cells become diseased when this process goes awry.
Reference: Spatiotemporal Control of Intracellular Phase Transitions Using Light-Activated optoDroplets. Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, Brangwynne CP. Cell. 2017, January 12.
Type 2 diabetes (T2D) is a complex disease that affects more than 29 million Americans, a number that is expected to increase in the coming decades. T2D risk factors include, but are not limited to, genetic mutations, obesity, physical inactivity, and increased age. These numerous risk factors highlight how both genetics and environmental influences can contribute to T2D. In order to develop better methods for early detection and disease treatment, scientists need a better understanding, at both the research and clinical levels, of how this disease occurs and progresses.
To gain a better appreciation of T2D, the research community must study it from different viewpoints. This concept is exemplified by the NIH Common Fund, which strives to support research relevant to multiple diseases and conditions, developing tools and resources from different biological perspectives that others can apply to specific questions. Several different scientific fields have used support from the Common Fund to deepen our understanding of T2D.
Inherited risks, such as genetic mutations, as well as environmental risks, such as obesity, physical inactivity, and age, have all been linked to T2D. Due to the complexity of factors contributing to T2D, a single type of drug or treatment procedure is likely to be ineffective, and a more personalized approach to treat specific underlying causes is needed. A recent study, supported by the Common Fund’s Illuminating the Druggable Genome program, used advanced genetic and computer analysis methods to determine three distinct subgroups of 11,210 patients with T2D based on their clinical and genetic histories. Patients were pooled based on other medical conditions, such as heart disease, cancer, and kidney disease. The study found distinct patterns of clinical characteristics as well as unique genetic markers for each subgroup. These types of results will allow doctors to create better, more detailed treatment plans for T2D patients by targeting specific risks that may be connected to the disease and may help doctors develop an early warning system for T2D in patients with other medical conditions. In addition, these results highlight the value of precision medicine and show an approach that can be applied to other complex, multifactorial diseases to develop better treatment plans and improved patient outcomes. More information on the study can be found here.
In T2D, the body does not use insulin correctly, which increases the amount of glucose (sugar) present in the bloodstream. Insulin is a hormone made by the pancreas which moves around the body and allows your cells to use glucose properly. Currently, researchers look for changes in blood glucose levels in order to monitor how certain cells of the pancreas work. This method can be insensitive and is a poor marker for how pancreatic cells are working. It can also be invasive, resulting in poor quality data and loss of patient involvement. Recent work supported by the Common Fund’s New Innovator Award Program has developed a noninvasive, high resolution system to monitor how individual cells work in real time in biological tissue. Previous methods which used cells in a culture dish, which is a poor representation of biological tissue. What makes this technology even more powerful is that the method allows researchers to study cell growth and other biological functions in addition to glucose production. Knowledge of pancreatic cell roles will allow researchers to develop better T2D treatments by monitoring improvements in pancreatic cell function in a much more detailed, real-time, and less invasive way. The full study can be found here.
A new clinical study involving the Common Fund’s Human Microbiome Project aims to examine the microbiome of 100 at-risk individuals for T2D. Microscopic study of the healthy human body has demonstrated that microbial cells outnumber human cells by about ten to one. Until recently though, this abundant community of human-associated microbes remained largely understudied, leaving their influence upon human development, physiology, immunity, and nutrition almost entirely unknown. Researchers have found that there are differences in the gut microbiome between diabetics and healthy individuals, and have also shown that the microbiome can influence glucose levels in mice. The study is expected to reveal global changes in the microbiome of T2D at-risk individuals in great detail over time. This will allow researchers to not only better understand how the microbial cells in our bodies influence our health, but also identify new molecular targets to help diagnose, treat, or potentially prevent T2D in humans. More information on the clinical study can be found here.
It is clear that there are many factors that can contribute to developing T2D. By helping support research to develop different biological tools that answer difficult biological questions, Common Fund programs are helping researchers better understand complex diseases like T2D, and ultimately, helping many patients.
In a recent perspective, Dr. Cynthia Fuhrmann, a PI in the NIH BEST Consortium, suggests ways to strengthen biomedical career development. Dr. Fuhrmann highlights that the national conversation is progressing and moving away from ‘‘should we be providing career development to PhDs?’’ to ‘‘how do we do so effectively?” In the present academic environment, trainees often lack knowledge about available career options. Furthermore, trainees can be unprepared to chart their own career path, to develop professional skills, or to cultivate other skills specific to their intended career path. All of this complicates their transition into any career within or beyond academia. Because of this, Dr. Fuhrmann argues that we need a “culture that encourages the career development of our trainees, and enhances our educational approach such that career exploration and development of our trainees can occur in synchrony with their research.” The culture change is starting to happen and the academic community is beginning to understand and support the fact that traditional research-intensive positions are not the only means by which PhD graduates can meaningfully contribute to the biomedical research enterprise. To help enhance career preparation, Dr. Fuhrmann recommends that institutions embrace and support the fact that trainees seek a variety of scientific careers. To support this, institutions should work to better integrate professional skills and career development workshops, courses, and assignments into the required curriculum for all trainees. Ultimately, she recommends that institutions should invest in career development as a part of their academic mission. By doing these things, and gathering data and researching how well these efforts work, trainees will be better able to efficiently move into careers that will sustain our nation's biomedical enterprise. Institutions embracing this philosophy in their curricula will attract bright and talented trainees to their doors.
Enhancing Graduate and Postdoctoral Education To Create a Sustainable Biomedical Workforce. Hum Gene Ther. 2016 Nov;27(11):871-879.
Image courtesy of Human Gene Therapy
Investigators from the International Human Epigenome Consortium (IHEC), which includes Common Fund Roadmap Epigenomics Program grantees, have published a special collection of papers titled “Insights from the International Human Epigenome Consortium”. This collection includes 24 papers published in Cell and other Cell Press journals, plus 17 papers published elsewhere. This publication release demonstrates how the consortium’s epigenomic reference maps can help find answers to pressing questions related to the cellular mechanisms associated with numerous complex human diseases. For example, Common Fund Epigenomics grantee Dr. Aleksandar Milosavljevic and collaborators found that the epigenetic profiles of breast cancer cells are distinct from normal epithelial cells and that these epigenetic marks can be mapped to specific groups of cancer cells. This is significant because it enables the study of factors that drive tumor progression.
Building the Molecular Foundation of Alzheimer's Disease; How Multiple Common Fund Programs Develop Tools To Further Our Understanding
Alzheimer’s disease is among the leading causes of death in both the United States and the world. As medical advances increase life expectancy, it is estimated the number of Alzheimer’s cases will double over the next 25 years, leading to a significant economic and social burden. Despite our increasing understanding of Alzheimer’s disease, there is still much we do not know, primarily because the disease can attack individuals in many different ways.
Common Fund programs, while not focused on specific diseases or conditions, often support cutting edge and transformative projects that have the potential to impact many different diseases. A variety of Common Fund-supported projects have developed ideas to examine Alzheimer’s disease from different viewpoints. This multipronged model has allowed for significant advancements in our ability to understand how this disease works across different populations and individuals and may lay the foundation for future diagnostics and treatments.
A major purpose of Common Fund projects is to develop innovative research tools and ideas to support diverse research goals. A common thread amongst many diseases, such as cancer, diabetes, or Alzheimer’s disease is the discovery of chemicals within our bodies, called biomarkers, which change as the disease develops. Two Common Fund programs supporting the development of new biomarker detection tools are Epigenomics, which studies how different factors can turn our genes on or off at different times, and Metabolomics, which studies how chemicals in our bodies are broken down or used for energy. One of the biggest hurdles when studying Alzheimer’s disease is that distinct biological changes happen in our bodies long before doctors are able to diagnose the disease. Thus, by the time we know there is a problem, it is too late for treatment. Researchers have used the tools developed by Epigenomics and Metabolomics Common Fund programs to make great strides in finding innovative biomarkers for Alzheimer’s disease. For example, one study used tools from the Epigenetic program to determine the brains of patients with Alzheimer’s disease had increased changes (methylation) to their DNA compared to patients without the disease. Studies like these are the first step to better understanding the biological changes that occur in patients with Alzheimer’s disease. Researchers now have specific targets to look for in blood and other tissues to see if the same change occurs. Tools developed by the Metabolomics program help these types of studies to be performed. Researchers used methods developed by the Metabolomics program to find that patients with elevated levels of specific chemicals (fats, such as cermaide) had a higher likelihood of developing Alzheimer’s disease. These are just two of many examples of how research advances from two very different Common Fund programs can contribute to our understanding of Alzheimer’s disease.
In addition to finding biomarkers, many Common Fund programs have developed tools and resources that researchers have used to study changes in biological processes in Alzheimer’s disease. One interesting study used resources from the Metabolomics program to show that cells in the brain of Alzheimer’s patients were breaking down parts of other cells to be used as sources of fuel. These results suggest that the brains of Alzheimer’s patients may have lower energy compared to non-diseased individuals, and also highlights how loss of brain function may occur as one cell type is lost or damaged to support its neighbor. To gain a deeper understanding of how the disease works and to support data found in human patients, researchers often use animal models. One program that highlights the importance of animal models is the Knockout Mice Phenotyping (KOMP2) program, which supports efforts for researchers to generate and characterize mice that have specific genes removed. Other researchers can then use these mice to study how the genes influence diseases. Through KOMP2, the Common Fund has helped support the generation of many mouse models that have been used to study Alzheimer’s disease, such as the Alzheimer’s disease modifier genes 1-5 (Azdm1-5) or the Presenilin 1 and 2 knockouts (Psen1/2).
Several awards within the Common Fund’s High Risk High Reward (HRHR) program are also advancing research about Alzheimer’s disease. The HRHR program supports highly risky and innovative ideas that have the potential for exceptional payoff. These awards have allowed researchers to develop innovative biomarkers, more precise animal models, and groundbreaking brain imaging studies to help identify early warning signs of Alzheimer’s disease. HRHR awardees are also investigating how common, everyday mechanisms such as sleep and stress may contribute to the development of Alzheimer’s disease.
Not only do Common Fund programs contribute to understanding how Alzheimer’s disease starts and progresses, there is also substantial support for the development of future potential therapeutic studies. The Regenerative Medicine and Regulatory Science programs are working to provide resources that one day may be used by researchers to help patients with Alzheimer’s disease. Researchers supported by the Regenerative Medicine program are developing resources to accelerate development of new therapies using induced pluripotent stem cells to treat multiple diseases. These fundamental resources may one day be used by scientists to understand how to repair the neurons that are damaged in the brain during Alzheimer’s disease. The Regulatory Science program is developing interconnected model systems of different organs and cells in our body to not only better understand how cells communicate within a larger system, but to also use these models to see how organs as a whole respond to toxins, drugs, and other outside influences. These resources may one day allow scientists to develop a mini-brain model that mimics Alzheimer’s disease, allowing researchers to possibly move away from traditional animal models and to see how potential drugs may act in an environment more similar to the human disease.
Drs. Mary Dickinson and Steve Murray and collaborators, as part of the Common Fund’s Knockout Mouse Phenotyping Program (KOMP2) and International Mouse Phenotyping Consortium (IMPC), have been using mouse models to study essential genes, or genes that are necessary for survival. In the absence of these genes, mice die as embryos, bringing up unique challenges for their analysis. However, this embryonic death also provides evidence for the critical role these essential genes play in normal growth and development in both mice and potentially humans. As part of the overall KOMP2/IMPC effort, researchers developed a strategy to more carefully study the function of these essential genes. In their strategy, they identify and describe the exact time of mouse lethality, assign phenotypes, and use a “reporter gene” to mimic the normal expression of the gene of interest in order to describe the function of these genes. This paper, High-throughput discovery of novel developmental phenotypes, is the first international, systematic effort to comprehensively characterize the functions of these genes in mice. This effort also includes 3D high-resolution imaging of embryos that are accessible on the IMPC portal. This imaging includes use of new and high level imaging that provides a level of detail not seen until now. For example, not much is currently known about disease associations with the gene Chtop. However, imaging of Chtop knockout embryos indicate abnormal eye development and neural tube defects, suggesting critical roles for this gene in normal eye and neural tube development. These results open a new line of research for scientists interested in studying development and diseases of the eye and nervous system. These new embryonic data add to the growing understanding of genetic mechanisms required for normal embryonic growth and development, while also providing insight into human developmental disorders and gene discovery for non-lethal conditions. As part of the full IMPC data, these data are contributing to this active and growing IMPC resource that will benefit the scientific community for years to come. Data are provided in real time to the entire research community, creating an “open access” environment allowing investigators to rapidly use the data to help their own research.
More information about the mice phenotyped through IMPC here.
In the news: Read a press release from the Jackson Laboratory about the study.
High-throughput discovery of novel developmental phenotypes. Dickinson ME, Ann M, Flenniken AM, Ji ,et al. Nature. 2016 September 14 (online).
Some genetic tests may misdiagnose heart condition in African Americans
Using updated information from detailed genetic databases, researchers found that genetic differences originally thought to be causative in the heart condition hypertrophic cardiomyopathy were actually harmless. These benign differences were up to 150 times more common in African Americans than in Americans of European descent. This means that African Americans were more likely to be prescribed needless tests, screening, and possibly even treatments. Dr. Isaac Kohane, a study author and NIH Common Fund grantee, says that including racially and ethnically diverse populations in clinical trials and genetic sequencing efforts is vital to ensuring information extracted from those efforts is relevant to more people. In fact, the researchers found they could accurately predict whether a genetic difference was harmful or benign 80% of the time in a study of 200 participants when one-third of the participants were African American. The study has important implications for personalized medicine where treatment decisions need to be based on data that take into account a person’s race and ethnicity.
Dr. Kohane was supported by a Common Fund grant for the Informatics for Integrating Biology and the Bedside (i2b2) center, one of the National Centers for Biomedical Computing.
In the news: Read a press release from Harvard Medical School about the study.
Reference: Genetic Misdiagnoses and the Potential for Health Disparities. Arjun K. Manrai, Birgit H. Funke, Heidi L. Rehm, Morten S. Olesen, Bradley A. Maron, Peter Szolovits, David M. Margulies, Joseph Loscalzo, and Isaac S. Kohane. New England Journal of Medicine. August, 2016; 375:655-665.
Marie Bragg, a 2015 Early Independence awardee, found music celebrities popular among adolescents tend to endorse unhealthy food and beverages. Bragg quantified the number and type of food or beverages endorsed by music celebrities and measured the nutritional value of the products. The popularity of the celebrities with adolescents was assessed using Teen Choice Award data. Seventy-one percent of endorsed non-alcoholic beverages were sugar-sweetened, and 81% of endorsed foods were nutrient poor. While the study does not examine how celebrity endorsement influences consumption, with the rise of obesity among teenagers, celebrity endorsement of unhealthy foods can send the wrong message to youth.
- Popular Music Celebrity Endorsements in Food and Nonalcoholic Beverage Marketing. Bragg MA, Miller AN, Elizee J, Dighe S, Elbel BD. Pediatrics. 2016 Jul;138(1). pii: e20153977.
- In the News: This Is How Much Celebrities Get Paid To Endorse Soda And Unhealthy Food
- In the News: Eat and Drink Like a Music Celebrity?
- In the News: Most Celebrity-Endorsed Food and Drink Unhealthy
- In the News: Almost All Food, Beverage Products Marketed by Music Stars are Uhealthy
Epigenomics grantee Dr. Jacob Hooker and collaborators have used a new neuroimaging tool to show, for the first time, where genes are being turned off or on in living human brains. Histone deacetylases (HDACs) are enzymes that regulate gene expression through epigenetic modifications and are therefore useful therapeutic targets. Using a specific HDAC imaging probe called Martinostat and positron emission tomography (PET) scanning, Dr. Hooker’s group has visualized HDAC expression in the living brain of eight healthy volunteers. In addition to observing distinct regions of HDAC expression within human brains regions, they also saw strikingly conserved regions of HDAC expression levels between these individuals. These conserved patterns within and between healthy individuals are significant because this lays the groundwork for understanding epigenetic information in the human central nervous system (CNS) and related diseases. “I’m hoping these colorful maps let us compare healthy brains with the brains of people with schizophrenia, Alzheimer’s, and other diseases,” said Hooker. The authors conclude that this work provides a “critical foundation for how to quantify epigenetic activity in the living brain and in turn accomplish HDAC inhibition in the CNS as a therapy for human brain disorders”.
In the news: In living color: New technique sees gene activity in human brains, STAT News. Also featured on PBS Newshour and Scientific American.
Reference: “Insights into neuroepigenetics through human histone deacetylase PET imaging.” Wey HY, Gilbert TM, Zürcher NR, She A, Bhanot A, Taillon BD, Schroeder FA, Wang C, Haggarty SJ, Hooker JM. Science Translational Medicine. 2016 August 10.
X-inactivation is the process by which one of the two X chromosomes present in female mammals is inactivated. This prevents them from having twice as many X chromosomes gene products as males, who only have a single X chromosome. A Barr body is the structure inside of the nucleus that consists of the inactive X chromosome. Although the Barr body appears to be a condensed blob under a microscope, a new study from 4D Nucleome grantee Job Dekker, Ph.D. and collaborators reveals a highly elaborate structure. Using a variety of methods, including chromosome conformation capture technologies and mouse models, they found that the inactive X chromosome is actually composed of two distinct lobes of inactive DNA. They also found that these lobes were separated by highly repetitive segments of DNA called “microsatellite repeats”. When these microsatellite repeats were removed, the bi-lobed chromosome structure vanished. In another finding of this study, a limited number of active genes in these lobes were separated by topologically associated domains (TADs), which are regions of the genome where DNA interactions frequently occur. This finding is significant because it suggests that TADs may organize gene expression in the inactive X chromosome, at least in neural progenitor cells.
“This is the most detailed molecular view we’ve been able to obtain of the DNA inside the Barr body,” said Dekker. “Under a microscope, the inactive X chromosome is very different than other chromosomes; it looks like a condensed, undefined, inactive ‘blob.’ Our study, using a range of experimental approaches including imaging and genomic methods, describes something else entirely: a highly organized and elaborate structure, rich in features that may silence or activate genes all along the chromosome.”
In the news: Read the press release from the University of Massachusetts Medical School here.
Reference: Structural organization of the inactive X chromosome in the mouse. Giorgetti L, Lajoie BR, Carter AC, Attia M, Zhan Y, Xu J, Chen CJ, Kaplan N, Chang HY, Heard E, Dekker J. Nature. 2016 July 28.
Finding the Needle in a Haystack: New Tool to Find Significant Results from Genome-Wide Association Data
Genome-wide association studies (GWAS) have the ability to reveal thousands of genetic variants associated with a particular disease or trait (cancer, height, etc.). While GWAS studies have become a powerful new tool for researchers, they also reveal thousands of potential variants of which many are not directly related to a condition but merely associated. Finding the genetic changes that drive a disease or trait can be difficult, especially when the variants are in non-coding regions of the genome. While non-coding regions of the genome do not directly express genes, they often regulate the expression of coding areas. Dr. Sabeti, New Innovator Awardee, and colleagues have devised a new tool that can directly identify which variants are affecting expression on a very large scale. The group was able to take an existing technology (published as a companion paper in the same issue of Cell) and scale it to examine more variants while also reducing noise and increasing the sensitivity of the test. This new resource should prove to be highly effective to many researchers who already have access to GWAS data but are having difficulty interpreting their results.
Broad Institute News: A massive approach to finding what's "real" in genome-wide association data
Direct Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay. Tewhey R, Kotliar D, Park DS, Liu B, Winnicki S, Reilly SK, Andersen KG, Mikkelsen TS, Lander ES, Schaffner SF, and Sabeti PC. Cell. 2016 Jun 2; 65(6):1519-29.
The human brain contains around a hundred billion neurons densely packed into three pounds of tissue. Neurons differ from one another in structure, function, and genetic landscape. Although this complex neuronal diversity is fundamental to human brain function, it is still not known how many different types of neurons there are in the brain. This lack of knowledge has impeded our understanding of how the brain functions in health and human disease. Toward understanding brain neuron diversity, Single Cell Analysis Program researcher Dr. Kun Zhang and collaborators examined the gene expression profiles of individual neurons, isolated from post mortem human brain tissue, using single cell RNA sequencing. 3227 sets of single-neuron data from six distinct regions of the cerebral cortex were generated and 16 neuronal subtypes were identified. The authors report that this robust and scalable method lays the “groundwork for high-throughput global human brain transcriptome mapping”. This approach could provide insight into brain function, and potentially disease mechanisms, through distinct profiles of gene expression signatures.
Reference: Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016 June 24.
Read additional commentary in The Scientist: Single-Cell RNA Sequencing Reveals Neuronal Diversity.
Transcription occurs when a particular segment of DNA is expressed into RNA. This process appears to take place in intermittent bursts and has been observed in organisms ranging from bacteria to humans. Transcriptional bursting is a term that describes this highly variable occurrence. Enhancers are short regions of DNA that can significantly increase the likelihood that a gene will be transcribed. There are hundreds of thousands of enhancers in the human genome, many of which precisely regulate patterns of gene expression that are required for the differentiation and growth of cells and tissues. To better understand the relationship between transcriptional bursts and enhancers, Dr. Michael Levine, a 4D Nucleome grantee, used quantitative analysis and live-imaging methods in Drosophila embryos in real time. Using this model organism, they report that enhancers regulate the frequency of transcriptional bursts and that strong enhancers produce more bursts than weak ones. They also report that shared enhancers can drive coordinated bursting of two different reporter genes, suggesting the importance of chromosome architecture in control of gene expression.
Reference: Enhancer Controls of Transcriptional Bursting. Fukaya T, Lim B, Levine M. Cell. 2016 June 9.
DNA is not randomly arranged in the nucleus. Instead, nuclear organization is tightly controlled. For example, insulated neighborhoods are loops of DNA that function to maintain normal expression of genes within and outside of the loop. Defects in nuclear organization and the folding of the human genome have been linked to cancer. In a new study, 4D Nucleome investigator Dr. Job Dekker, Ph.D., Howard Hughes Medical Institute Investigator, University of Massachusetts Medical School, and collaborators investigated the causal relationship between chromosome structure and oncogene activation. Oncogenes are genes that have the potential to cause cancer, when activated through dysregulation of gene expression. Using DNA sequences from tumors and targeted mutations in cancer cell lines, they show that disruption of insulated neighborhoods can activate oncogenes. This suggests that disruption of chromatin architecture is causally linked to the formation of tumors. This work represents a step toward understanding 3D chromosome structure and the authors conclude that “understanding these regulatory processes may provide new approaches to therapeutics that have on impact an aberrant chromosome structure.
Activation of proto-oncogenes by disruption of chromosome neighborhoods. Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, Reddy J, Borges-Rivera D, Lee TI, Jaenisch R, Porteus MH, Dekker J, Young RA. Science. (6280) 1454 – 8.
Gaining access to the brain is a major obstacle for central nervous system drug development and delivery and non-invasive approaches are greatly needed. Research supported by the Extracellular RNA Communication Program is laying the foundation for the possibility of using extracellular RNAs (exRNAs) to treat brain cancers and other diseases. In this study, Dr. Zhang and colleagues use a mouse model to demonstrate the feasibility of treating brain-related diseases with intranasal delivery of RNA. They use a unique type of exosome-like nanoparticle, called a Grapefruit-derived Nanovector, to deliver an RNA of interest to the brain. These nanovectors can be generated from grapefruit plants in large quantities. Furthermore, Zhang et al. find that a specific RNA with potential therapeutic effects, miR17, can be effectively delivered to the brain using these grapefruit vectors without observable side effects in the mice. Remarkably, not only can the RNA be delivered to a target location effectively, it can also inhibit tumor growth in cell culture and in the mice. Although more work is needed to verify the mode of action and potential utility in humans, this study demonstrates the potential for an effective noninvasive therapeutic agent for the treatment of brain diseases.
Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression. Zhuang, X., Y. Teng, A. Samykutty, J. Mu, Z. Deng, L. Zhang, P. Cao, Y. Rong, J. Yan, D. Miller and H. G. Zhang. Mol Ther. 2016 Jan 24(1): 96-105.
Image courtesy of the University of Louisville
Hongrui Jiang, a 2011 New Innovator, designed extremely small, super light-sensitive sensors inspired by the highly effective light-gathering retina of elephant nose fish. Inspired by the deep cup-like structures with reflective walls found in the elephant nose fish's retina, Jiang created a device that contains thousands of small light collectors with finger-like glass protrusions covered by reflective aluminum. Incoming light hits the fingers and is focused on the reflective walls, enhancing the image. The work is a step towards creating a contact lens that autofocuses within milliseconds that can be used to treat presbyopia, a stiffening of the eye's lens that makes it difficult to focus on close objects.
- Artificial Eye for Scotopic Vision with Bioinspired All-Optical Photosensitivity Enhancer. Liu H, Huang Y, Jiang H. PNAS. 2016 Mar 14;doi: 10.1073/pnas.1517953113.
- In the News: Fish and Insects Guide Design for Future Contact Lenses
- In the News: 'Fish-Eye' Contact Lens Auto-Focuses
The Human Microbiome Project not only served as a catalyst for microbiome research across the National Institutes of Health (NIH), it stimulated interest in the larger growing field of microbial ecology. In the spring of 2015, the Office of Science Technology and Policy (OSTP) chartered a committee of government scientists in 14 agencies to form the Fast Track Action Committee-Mapping the Microbiome (FTAC-MM). The FTAC-MM was charged with conducting a portfolio analysis of human-, animal- and habitat-associated intramural and extramural microbiome research support over fiscal years 2012-2014. The analysis focused on the use of genome-enabled approaches to study microbial communities. It also endeavored to classify the studies into basic or applied research or tools and resource development and categorized the research into eight microbial categories and eight environments.
The results of the FTAC-MM analysis were published in the inaugural issue of Nature Microbiology (January 2016) in a paper titled “An Assessment of US Microbiome Research” . The analysis showed that microbiome research received a high level of support ($922M) in fiscal years 2012 -2014 across multiple federal agencies, with NIH-supporting the bulk of the research at 59%. The majority of the research was in human subjects (37%) or animal models (29%) and focused on the gut microbiome.
Other habitats that were examined included everything from studies on oceanic microbiomes (National Science Foundation) to the microbiomes of pollinators (U.S. Department of Agriculture), to the microbiomes of soils from the arctic, tropics, wetlands and grasslands (multiple agencies). About 70% of all research included in the analysis focused on total microbial community studies, which verified that the analysis captured the appropriate research.
A number of needs for the future health and growth of the field were identified, including the need for references and standards for the field, microbiome databases linking data from multiple habitats, further development of methods to study the functional properties of the microbiome and the need to train students in microbial ecology, multidisciplinary research and hypothesis-driven study design. Both the report and paper concluded with the recognition that the diverse group of governmental agencies with different missions and different constituencies arrived at the same common needs for advancing the field.
An assessment of US microbiome research. Stulberg E, Fravel D, Proctor L, Murray D, LoTempio J, Chrisey L, Garland J, Goodwin K, Graber J, Harris MC, Jackson S, Mishkind M, Porterfield DM, Records A. Nature Microbiology. 11 January 2016.
Chromatin is a complex of genomic DNA and proteins that make up the chromosomes within the nucleus of a cell. The organization of genomic material into chromatin is presumed to play an important role in regulating expression of genes. However, the precise relationship between spatial genome organization and expression of resident genes in health and disease remains unclear. Toward understanding 3D genome architecture and its relationship to gene regulation, 4D Nucleome researcher Dr. Yijun Ruan, Ph.D., a Jackson Laboratory Professor, Florine Deschenes Roux Chair and Director of Genome Sciences, and his team worked with international collaborators to identify a framework in which genes are organized and transcribed at the chromosomal level.
For these studies, the authors used advanced 3D genome mapping technologies and simulation, as well as super-resolution microscopy. These models revealed higher order chromosome folding and specific chromatin interactions, mediated by the chromatin proteins CTCF and cohesin. These chromatin structures suggest a “barrier” between genes being actively transcribed and those that are not. Importantly, these studies further uncovered potential mechanistic links between genetic mutations associated with specific disease and chromatin topology.
“The significance of this paper lies in our advanced 3D genome mapping strategy,” Dr. Ruan said, “which allowed us to reveal, for the first time, the higher-order and detailed topological structures of the human genome mediated by CTCF and cohesin, and the relation to gene transcription regulation carried out by RNA polymerase II. This publication is also timely adding new excitement to the recently initiated 4D Nucleome program by NIH." For additional information, read The Jackson Laboratory news release.
CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. Tang Z, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, Trzaskoma P, Magalska A, Wlodarczyk J, Ruszczycki B, Michalski P, Piecuch E, Wang P, Wang D, Tian SZ, Penrad-Mobayed M, Sachs LM, Ruan X, Wei CL, Liu ET, Wilczynski GM, Plewczynski D, Li G, Ruan Y. Cell. (7) 11611 – 27.
Advances in DNA sequencing technologies have been a boon for modern human microbiome studies. However, until very recently, these technologies have also had an important limitation. The most common methods have involved the extraction of DNA from these microbiomes and analysis of numerous short stretches of this DNA by sequencing. As the typical microbiome is comprised of thousands of microbial species and millions to trillions of microbial cells, it has been very difficult to re-assemble these short stretches, known as sequence reads, back into the complete genomes of these microbes. Further, with the average bacterial genome about 3,000 base pairs (bp) and the average stretch of DNA sequence read about 100-400 bps, the process of re-assembling millions of these genomes from these short reads has been very difficult.
Reassembling genomes is particularly limiting for performing metagenomics analysis which seeks to uncover the diversity of microbial communities directly from environmental samples, like from the gut tract or skin microbiomes. Finally, although the majority of microbial diversity in microbiomes is found at the subspecies and strain levels, current sequencing technologies have not been able to produce the level of detail needed to get at this level of microbial diversity.
A new study, published December 14, 2015 in Nature Biotechnology, from the laboratory of HMP awardee Dr. Michael Snyder at Stanford University, addresses this important biological problem in the microbiome field with a technical solution. The technique described in Dr. Snyder’s study, used a new sequencing technology, known as TruSeq synthetic long read sequencing technology, to dive deeper into the human gut microbiome. This technology yields 30,000-40,000 bp long reads and allows the investigators to more completely assemble whole microbial genomes from this long read sequence data. More importantly, they were able to consistently recover sufficiently long sequences that allowed them to identify sub-species and strains of bacteria and specific metabolic genes in these strains from these gut microbiome samples and thereby capture the true diversity and metabolic abilities of a microbial community.This now unmasked diversity may lead to new approaches to understanding the specific roles of these microbial strains in human health and disease.
Synthetic long-read sequencing reveals intraspecies diversity in the human microbiome. Kuleshov V, Jiang C, Zhou W, Jahanbani F, Batzoglou S, Snyder M. Nature Biotechnology. 14 December 2015. 10.1038/nbt.316.
G-protein-coupled receptors (GPCRs) constitute the largest family of proteins encoded by the human genome. With more than 26% of FDA approved drugs acting through them, they are also the most prolific therapeutic targets. However, a large fraction of these receptors are understudied or are considered to be ‘orphan’ receptors and their functions and the chemical signals that control them are not known. Uncovering the biology of these understudied GPCRs could lead to new inroads in therapeutic interventions, which is why the research of Dr. Bryan Roth (University of North Carolina at Chapel Hill) and Dr. Brian Shoichet (University of California, San Francisco) is so exciting.
These Investigators from the Common Fund’s Illuminating the Druggable Genome program, used an innovative approach to uncover the function of orphan GPCRs. They combined physical and structure-based screens to discover ligands and optimize probes for two under characterized GPCRs –GPR68 and GPR65. GPR68, also known as OGR1, is an orphan receptor that is highly expressed in the brain. The researchers used a newly discovered molecule “ogerin”, which turns on GPR68, to understand the role of this receptor in the brain by monitoring several behaviors in mice. The investigators found that mice that were given ogerin had a dampened response to contextual-based fear memory. The hippocampus is central to this behavior and GPR68 was found to be highly abundant in this brain region. Mice that lacked the GPR68 receptor were not affected by ogerin.
The researchers used the same technique to discover molecules that interacted with another orphan receptor, GPR65. These results not only demonstrate that this approach is applicable to the majority of understudied GPCRs, but it has the potential to be expanded to other classes of proteins as well.
Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Huang XP, Karpiak J, Kroeze WK, Zhu H, Chen X, Moy SS, Saddoris KA, Nikolova VD, Farrell MS, Wang S, Mangano TJ, Deshpande DA, Jiang A, Penn RB, Jin J, Koller BH, Shoichet BK, Roth BL. Nature. 26 November 2015. 527(7579):477-83.
Different Treatments for Crohn’s Disease in Pediatric Patients Have Distinct Effects on the Gut Microbiome
Changes in diet and application of antibiotics and/or anti-inflammatories are the typical interventions used as the standards of care for the treatment of Crohn’s disease (CD), a subtype of inflammatory bowel disease. One major characteristic of CD is an imbalance in the normal composition of the microbiota in comparison to healthy controls. A recent study from Human Microbiome Project awardee Dr. Frederic Bushman and colleagues at the University of Pennsylvania sought to systematically separate the effects of these interventions on the gut microbiomes of a cohort of pediatric CD patients.
Each intervention independently affected the microbiome in CD patients. In particular, antibiotic use seemed to worsen dysbiosis by reducing the abundances of some microbes, increasing the abundances of fungi or both, thus aggravating the condition. Anti-inflammatories, on the other hand, reduced gut microbiota dysbiosis, thereby potentially supporting recovery from CD. Certain defined diets resulted in rapid changes in the gut microbiome suggesting diet may also be an effective treatment for CD.
Since CD patients often have higher rates of gut epithelial cell shedding and/or blood in their stool, stool samples can be sequenced to use as an early indicator of this disease, even before occult blood can be detected. This study suggests that analysis of the microbiome may lead to useful biomarkers for determining the efficacy of standard treatment for CD and for providing additional tests for early detection of CD.
Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, Bittinger K, Bailey A, Friedman ES, Hoffmann C, Albenberg L, Sinha R, Compher C, Gilroy E, Nessel L, Grant A, Chehoud C, Li H, Wu GD, Bushman FD. Nature. 14 October 2015. 18(4): 489-500.
The Molecular Libraries and Imaging Program Continues to Pay Dividends After Leaving the Common Fund
The Common Fund’s Molecular Libraries and Imaging (MLI) Program has made promising inroads in the development of new therapeutics for human disease. A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute (TSRI), which was a part of the MLI program, was a precursor to the drug candidate ozanimod; which is currently in two Phase III clinical trials –one for patients with relapsing multiple sclerosis and the other in patients with ulcerative colitis. Dr. Hugh Rosen, a professor at TSRI was a Center Principal Investigator in the MLI program and one of the discoverers of ozanimod. Researchers screened the NIH MLI collection to find allosteric modulators of the sphingosine 1 phosphate receptor 1 (S1P1). Compounds identified in the screen were then optimized for safety and effectiveness in man, resulting in the clinical candidate ozanimod (formerly RPC1063).
Launched in 2004 as one of the original NIH Roadmap programs, the primary intent of MLI was to empower the research community to use small molecule compounds (probes) to study the functions of genes and pathways. The most surprising and encouraging findings, however, have been the great strides MLI is making in drug discovery. The topic of the “Valley of Death” –getting promising scientific breakthroughs made at the bench to the patients, continues to be a high priority area in the biomedical community. The academic approach employed by MLI, in conjunction with the Common Fund’s Structural Biology program, allowed for the exploration of basic biological mechanisms that led to the discovery of a lead compound, the crystal structure of S1P1, and the discovery of the binding site for the compound.
Dr. Rosen is now on the hunt for another drug candidate that has its roots in the MLI program. He will co-direct, as part of the NIH’s Blueprint Neurotherapeutics Network, a project that focuses on a candidate migraine treatment to be tested in preclinical studies. The grant for this project is funded through the National Institute of Neurological Disorders and Stroke.
Celgene bets big on Scripps-originated autoimmunity candidate. Cully M. Nature Reviews Drug Discovery. 21 August 2015. 14(9): 595.
EurekAlert! Press Release from Scripps Research Institute
Epigenetic marks are chemical modifications to DNA or DNA-associated proteins that regulate gene expression without changing the DNA sequence. These marks act in many important processes including development, aging, health, and disease; because of this they are targets for therapeutic intervention and intense research activity. Exciting new technologies, such as the CRISPR/Cas9 system used for gene editing (adding, deleting or changing the sequence of targeted genes), have opened new possibilities and sparked a transformation in genetic and epigenomic research (the study of epigenetics across the full genome). Researchers that are funded through the Common Fund’s Epigenomics Program and New Innovator Award at Dr. Gersbach’s lab at Duke University have recently exploited CRISPR/Cas9 technologies to develop state-of-the-art tools that are shaping new discoveries.
Using the powerful CRISPR/Cas9 system, Dr. Gersbach and colleagues made a fusion protein that activates particular genes by directly targeting specific histones for chemical changes, such as acetylation-one type of epigenetic mark. Currently, studying the function of particular epigenetic marks has largely been limited to statistical associations with gene expression patterns, and not to direct functional studies. This unique molecular tool allows researchers to surmount this challenge. With this system, the group showed this directed acetylation to promoter and enhancer regions is sufficient to turn on gene expression. This novel system provides a powerful tool for researchers to directly turn on or off targeted genes of interest thereby allowing direct functional analysis of site-specific epigenetic modifications.
In another innovative application of CRISPR-Cas9 technology, Dr. Gersbach and colleagues were able to control gene expression by simply turning light on or off. They developed a system where they made two fusion proteins, fusion proteins are made by the joining of two or more genes that originally coded for separate proteins. One protein consisted of an inactivated Cas9 protein fused with a plant protein called CIB1 and the other protein fused a transcriptional activation domain to cryptochrome 2 (CRY2). When both proteins and a guide RNA are present in cells and illuminated with blue light, the two fusion proteins pair up, bind to their DNA, and turn on gene expression. Future application of this innovative technique could allow researchers to target any gene in an organism and turn it on or off with the switch of a light, which has amazing potential to transform genetic engineering.
Epigenome Editing by a CRISPR-Cas9-Based Acetyltransferase Activates Genes from Promoters and Enhancers. Hilton, I. B., A. M. D'Ippolito, C. M. Vockley, P. I. Thakore, G. E. Crawford, T. E. Reddy, and C. A. Gersbach. Nature Biotechnology. 33(5): 510-517.
A Light-Inducible CRISPR-Cas9 System for Control Of Endogenous Gene Activation. Polstein, L. R., and C. A. Gersbach. Nature Chemical Biology. 11(3): 198-200.
NIH-Funded KOMP2 Program Leads the Way in Efforts to Ensure Reproducibility and Enhance Transparency in Research
Researchers funded by the National Institutes of Health’s Common Fund Knockout Mouse Phenotyping Program (KOMP2) are making efforts to improve methods of data collection and reporting in animal research, with the goals of making these processes more accessible and research findings more reproducible. The KOMP2 program, a part of the International Mouse Phenotyping Consortium (IMPC), aims to extensively test and generate data about mice with disrupted, or “knocked out,” genes to help better understand human biology and disease. KOMP2 researchers are examining the clinical and physical characteristics – phenotypes – of mice carrying mutations in approximately 20,000 specific genes across the genome. They hope to systematically describe each gene and its biological function.
In 2010, the United Kingdom National Centre for the Replacement, Refinement, and Reduction of Animals in Research (3R) introduced the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines . These guidelines were designed to address an emerging problem in biomedical animal studies -- a lack of reproducibility of research results -- and improve the overall communication of research findings. The ARRIVE guidelines consist of a checklist to be used when submitting manuscripts that include animal research. They lay out reporting requirements to ensure all the information is available to allow fully reproducible research.
To enhance and embrace reproducibility in the IMPC large-scale research data collection and analyses efforts, KOMP2-funded investigators modified the ARRIVE guidelines to apply them to the large international database housing all the program data . The investigators described the process and challenges of applying the guidelines to the IMPC database May 20, 2015, in PLoS Biology. Their efforts assessed and documented how each of the IMPC centers carried out experimental procedures; details on how the data were obtained are available for download from the IMPC web portal. Investigators also developed a new and standardized language for the IMPC consortium, allowing all phenotypic data to be described in the same way and compared across research sites.
Applying the ARRIVE Guidelines to an In Vivo Database. Karp N, Meehan T, Morgan H, Mason J, Blake A, Kurbatova N, Smedley D, Jacobsen J, Mott R, Iyer V, Matthews P, Melvin D, Wells S, Flenniken A, Masuya H, Wakana S, White J, Lloyd KC, Reynolds C, Paylor R, West D, Svenson K, Chesler E, de Angelis M, Tocchini-Valentini G, Sorg T, Herault Y, Parkinson H, Mallon A, Brown S. PLOS Biology. 20 May 2015.
Smoking remains the leading cause of preventable illness and death despite the implementation of national policies, behavioral programs, and pharmacological treatments that have helped decrease smoking rates in the US. One promising line of research in smoking cessation relies on findings from the field of behavioral economics, which applies what we know about how people make health-related decisions to the design of health-behavior change interventions. Often, interventions informed by behavioral economics make use of financial incentives to encourage healthy behaviors and promote behavior change. Science of Behavior Change awardee Dr. Scott Halpern and colleagues at the University of Pennsylvania report their findings that financial incentive programs can lead to sustained cessation of smoking, and that the structures of incentive programs are differentially efficacious. Moreover, these incentive programs were more effective than the usual method of care, which included informational resources and free smoking cessation aids.
Study participants included CVS/Caremark employees or their relatives from across the US. After enrolling through a web-based research portal, participants were randomized into one of four incentive programs: individual reward, individual deposit, collaborative reward and collaborative deposit. The reward conditions differed by whether monetary rewards were paid based on individual or group success in smoking cessation, and by the initial, personal or collaborative monetary investment required of participants. The deposit conditions required individuals or groups to deposit some of their own money into an account that was enhanced by matched funds; they would get their own money back plus the additional funds if they successfully quit smoking, but lose their deposit and the additional funds if they were unsuccessful. The reward conditions did not require an initial investment of personal or collaborative funds, and so did not involve risk of loss of any participant’s own funds. Participants could opt out of assignment to any of the conditions, in which case they were re-assigned to another condition in the study. The logic behind the deposit conditions is that behavioral economics has shown that people are very motivated to avoid losses of their own funds; much more motivated than they are to gain rewards of the same or even larger size.
Researchers found that all four incentive programs were effective in promoting sustained smoking abstinence. Perhaps not surprisingly, fewer participants accepted conditions that required them to deposit their own money as part of their reward. Those who did accept the deposit condition, however, were substantially more successful in quitting smoking than those who accepted conditions that did not require an initial deposit. Interestingly, although the collaborative reward conditions have sometimes been found to be more efficacious in spurring behavior change in the past, this was not the case in this study.
Over all, this study underlined the fact that incentives-based programs can be very effective in helping people quit smoking, but the level of effectiveness depends on both the acceptability of intervention and structure of the incentive intervention. The deposit-based incentive intervention was far more efficacious for those who accepted it, but far less palatable to participants who were offered it. Future work in the area might target ways in which the acceptability of the more efficacious interventions could be increased, as well as increasing the efficaciousness of the interventions people are more likely to accept.
A randomized trial of four financial incentive programs for smoking cessation. Halpern SD, French B, Small DS, Saulsgiver KA, Harhay MO, Audrain-McGovern J, Loewenstein G, Brennan TA, Asch DA, Volpp KG. N Engl J Med. 2015
Read the Press Release from Perelman School of Medicine at the University of Pennsylvania.
We have known for many years that differences in the DNA that codes for our genes affect everything from our eye color to our susceptibility for certain diseases. Now we are finding that differences in genes are only part of the story. Differences in DNA that control when and how much genes are turned on and off can have a profound impact on health and disease. Researchers funded by the Genotype-Tissue Expression (GTEx) program have created a new data resource to help find out how differences in an individual’s genetic make-up can affect gene activity and contribute to disease.
Scientists can use the new resource to examine genes and gene regulation in many different types of human tissues at the same time. Investigators are collecting more than 30 tissue types from autopsy or organ donations and tissue transplant programs, and analyzing both DNA and RNA from samples. The project will eventually include tissue samples from about 900 deceased donors.
The resource is already beginning to bear fruit. One study looked at mutations called protein-truncating variants which shorten the protein-coding sequence of genes. Rare protein-truncating variants can lead to diseases like Duchenne muscular dystrophy. Most protein-truncating variants are harmless, and researchers found that each person’s genome carries about 100 of them. Another study looked at gene activity in a variety of tissues from multiple donors. Researchers found slightly fewer than 2,000 genes that vary with age, including genes related to Alzheimer’s disease. They also found more than 750 genes with differences in activity between men and women, with most in breast tissue.
The Genotype-Tissue Expression (GTEx) Pilot Analysis: Mutitissue Gene Regulation in Humans. The GTEx Consortium. Science, May 2015, Vol. 348 no. 6235 pp. 648-660. Read the article abstract.
Read the NIH Press Release.
Read more about the Genotype-Tissue Expression (GTEx) program here.
A list of companion papers to the GTEx Pilot Analysis is available via the GTEx Portal website.
Llamas have become the surprising focal point of a new technology that is aimed at making “nanobodies” more accessible to the research community. Nanobodies, considered to be the “little cousins” of antibodies, are therapeutic proteins derived from their larger antibody cousins. Antibodies are proteins produced by the immune system and used to identify and neutralize foreign elements in the body. They are extremely valuable research tools that are used routinely in basic research, diagnostic testing and therapeutics. Nanobodies can perform the same functions as antibodies; however, their small size and extreme stability make them attractive replacements. Although the appeal of using nanobodies in research has been clear for some time, the difficulties of producing them in sufficient quantities have limited their usefulness.
A discovery in llamas has changed the trajectory of nanobody production. Although not the original developers of nanobodies, a research team headed by Michael Rout, an investigator funded by the National Center for Dynamic Interactome Research http://www.ncdir.org/, within the NIH Common Fund’s National Technology Centers for Networks and Pathways (TCNPs) http://commonfund.nih.gov/bbpn/overview#TCNPs initiative has developed a novel approach to increasing nanobody production. Dr. Rout and his colleagues have designed a faster more direct technique to generate nanobodies, making them more accessible to the scientific community. They chose the llama instead of more common laboratory animals as a model for this method because llamas were found to make a unique subset of antibodies that can easily be turned into nanobodies. Faster production of these highly versatile nanobodies has the potential to transform research and catalyze scientific advances in a timeframe of weeks to months, instead of years.
A robust pipeline for rapid production of versatile nanobody repertoires. Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, Rout MP. Nat Methods. 2014 Dec;11(12):1253-60.
More than 440 researchers in 32 labs around the world participating in the Common Fund’s Roadmap Epigenomics program have generated and analyzed 111 reference human epigenomes. This is the largest collection to date of reference human epigenomes from a broad range of representative primary cells and tissues. A genome is defined as the DNA sequences present in a cell, and an epigenome refers to the chemical modifications and non-sequence changes to DNA and DNA-associated proteins. Currently, researchers are beginning to understand the many consequences of these chemical modifications, and early insights from this new analysis reveal that different epigenomic states are associated with differences in age, sex, and tissue type. The many companion papers describing additional analyses demonstrate the broad applicability of the resource. These studies examine the biological importance of epigenetic changes in the context of stem cell differentiation, obesity, Alzheimer’s disease, cancer, and cardiac disease. This remarkable accomplishment will usher in new scientific understanding of the complexity of the human genome at a deeper level and spur new research advances in human health and disease.
Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature, Feb. 18, 2015; 518; 317-330.
Read the NIH press release here.
Read more about the Epigenomics program here.
See video on the Epigenome by Nature here.
Scientists have long known that the metabolism of tumor cells differs from normal, healthy cells. However, it has been challenging to study tumor metabolism in living tumor cells from a large number of cancer patients. Metabolomics, a technique that allows scientists to analyze the molecules involved in metabolism, may change that. Researchers at the Common Fund-supported Resource Center for Stable Isotope-Resolved Metabolomics (RC-SIRM) looked at how the molecule glucose is broken down as part of the metabolism of patients with non-small-cell lung cancer. Shortly before surgery for tumor removal, the researchers injected patients with a form of glucose that is non-radioactively labeled. Using metabolomic techniques, researchers can follow how the labeled glucose is broken down by both the tumor cells and healthy cells from the same patient. As the glucose is broken down into component molecules, the label will remain with one or more of the components. These labeled components are a clue to which metabolic processes are active in the tumor.
The RC-SIRM team found that tumor cells broke down the glucose using two processes, glycolysis and the tricarboxylic acid cycle (TCA cycle). They also found that an enzyme involved in the TCA cycle, called pyruvate carboxylase, was produced in greater quantities in tumors compared to healthy tissue. Reducing the level of this enzyme in lab-grown human lung cancer cells reduced cell growth and interfered with the ability of these cells to form tumors in mice. This study by the RC-SIRM team demonstrates the exciting potential for metabolomic approaches to reveal new pathways and players in cancer metabolism that may become novel targets for cancer therapy and diagnostics.
RC-SIRM at the University of Kentucky is a Regional Metabolomics Resource Core funded through the Common Fund Metabolomics program. Learn more about the Metabolomics program.
Read the press release and watch the video from the University of Kentucky on this discovery.
The original research article was published in the Journal of Clinical Investigation. Read the article abstract.
New research has demonstrated that a destructive biological process involved in Alzheimer’s disease may hold promise as a novel treatment strategy for cancer. Anomalies in protein folding can generate harmful protein deposits within cells, called amyloids. These amyloid deposits underlie several neurodegenerative disorders in humans, particularly Alzheimer's disease. While amyloids are widely recognized as killers of neurons, a new study from New Innovator Awardee Dr. Chengkai Dai at The Jackson Laboratory reveals that cancer cells are also vulnerable to these toxic proteins. Cancer cells manage to contain deleterious amyloids by hijacking a cellular stress response that has evolved to counter protein misfolding, thereby sustaining the cancer cells’ vicious survival and growth. But importantly, this study also points to a possible means of countering this effect. Surprisingly, the authors’ findings reveal that cancer cells, unlike normal cells, constantly suffer heightened intrinsic stress. As a result, cancer cells are therefore particularly susceptible to extrinsic insults, including the activity of therapeutic agents that either perturb protein folding or subdue the defensive stress response. These agents efficiently induce the generation of amyloids within cancer cells and thereby exert potent anti-cancer effects. Thus, this study highlights a potential therapeutic strategy that harnesses the culprit behind neurodegenerative diseases to combat malignancy.
Tang et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF-1. Cell, 160, Feb 2015.
Pioneer awardee Dr. Joseph DeSimone has developed a device that uses electrical currents to drive chemotherapy drugs directly into tumors, potentially revolutionizing how doctors treat some of the most challenging types of cancer. Several types of cancer, notably pancreatic cancer, can be difficult to treat with surgery because the tumor can become enmeshed with healthy tissue and blood vessels. Intravenous chemotherapy treatment may also be ineffective, because these tumors often don’t have a good enough blood supply to deliver effective concentrations of the drug. To overcome these obstacles, Dr. DeSimone and colleagues at the University of North Carolina Chapel Hill, Duke University, and North Carolina State University designed a device that can be implanted directly on the tumor or applied to the skin to precisely deliver therapeutic doses chemotherapy drugs into the tumor, with minimal amounts of the drug spreading to other places in the body. In animal models of pancreatic and breast cancer, treatment with the device slowed tumor growth or even reduced tumor size. Treatment with the device was even more effective when combined with standard intravenous chemotherapy and radiation. These results suggest that the new approach pioneered by Dr. DeSimone may one day be added to the arsenal of weapons doctors use in the fight against cancer.
Byrne et al. Local ionophoretic administration of cytotoxic therapies to solid tumors. Science Translational Medicine, Feb 2015, 7(273).